|
|
|
EuroSciCon, Cineworld: The O2 Peninsula Square London London SE10 0DX United Kingdom
Wednesday, 05 November 2014 09:30 - Friday, 07 November 2014 17:00
The inexorable rise in the incidence of antibiotic resistance in bacterial pathogens, coupled with the disappointingly low rate of emergence of new,clinically useful antibiotics, has refocused attention on finding alternatives to antibiotic treatments. This event will discuss the potential utility of phages, probiotics, antimicrobial peptides, herbal medicines and immune modulation for treating human and animal disease. This event has CPD accreditation.Who Should Attend From researchers trying to find alternatives to therapies to pharmacists delivering treatments: any one with an interest in antibiotic alternatives would find this event of value.This event has an open oral and poster session. Abstract can be submitted on any subject related to antibiotic alternatives The deadline for abstract submissions for oral presentation is August 10th 2014Abstracts for poster presentation only can be submitted up to two weeks before the event. You can download the instructions for authors at www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf Keywords: Infection, Bacteriophage, Resistance,Toxin ,Purification Monolith,Yield ,Scaleable, cGMP, clinical trials, regulation, FDA, EMA, therapeutic use, lung, infection, Campylobacter, phage therapy, poultry, biofilms, Clostridium difficile, genomes, diagnostic, therapeutic, Metagenomics, ecology, microbial functioning, Genomics, Metabolism, Clostridium difficile, Pseudomonas aeruginosa, gastrointestine, probiotic, herbal, phage nanobiotechnology, antibiotic, antimicrobial peptides, Probiotics, adjunctive therapy, Bacillus probiotic, antagonistic activity, antibiotic-resistant pathogens, Antimicrobial peptides, flaviviruses, alphaviruses, bacteria, antibiotic alternatives, Antimicrobial peptides, antibiotic resistance, staphylococcal biofilms, Probiotics,Immunomodulators,Antiinflammatory, Antiarthritis,Lactobacilli, Androstenes; Steroids; Infection; viral and bacterial :Immune regulation, antibiotics, mult-drug resistance, octatpeptins, polymyxins, Maggot wound therapy, diabetic foot ulcer, chronic wound, wouund healing, antibiotic time, Androstenes; Steroids; Infection; viral and bacterial :Immune regulation, Quorum senser, device associate infection, anti-microbial agents, auto-inducers, Tuberculosis, host, signalling, phagosome, macrophage, Antibodies, peptides, antibiotics, immunomodulators,Innate Immunity, Macrophages, Immunoregulation, Nitric Oxid, Staphylococcus aureus, phage therapy, antibiotic resistance, phage-bacteria interactions
|
|
|
|
|
|
Organized by:
|
|
Euroscicon |
|
Invited Speakers:
|
|
Talks Include:
Novel Host Therapeutic Targets regulating M.tuberculosis infection Mr Cornelis Korbee, PhD Student, Leiden University Medical Center, The Netherlands
Pro- & Synbiotics - an alternative to antibiotics? Professor Stig Bengmark, Honorary Visiting Professor, Division of Surgery & Interventional Science, University College London, UK
HBD3 regulates matrix metalloproteinase production in human myeloid dendritic cells exposed to Porphyromonas gingivalis hemagglutinin B (HagB) Professor Kim A. Brogden, Director, Dows Institute for Dental Research, The University of Iowa, USA
Quorum sensing inhibitors as an alternate to conventional antibiotics Dr. Pragasam Viswanathan, Associate Professor, VIT University, India
Serendipity, bees, honey and wounds. Dr Matthew Dryden, Royal Hampshire County Hospital, UK
Antibiotic versus maggot therapy in diabetic foot ulcer Professor Chumpon Wilasrusmee, Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand
Development of bacteriocins for therapy of infections caused by Gram positive and negative MDR pathogens Dr Mathew Upton, School of Biomedical & Healthcare Sciences, Plymouth University, Plymouth, UK Bacteriophages for antistaphylococcal therapies – natural repertoire and limitations of choice Dr Hab Algorzata, Institute of Biochemistry and Biopysics of the Polish Academy of Sciences, Faculty of Agriculture and Biology, Warsaw University of Life Sciences, Poland
Host-Defense Peptides to New Antimicrobial Agents Dr Paul R. Hansen, University of Copenhagen, Denmark
Anti-microbial cationic peptides as a strategy for innovation in global health therapeutics for human infectious diseases Dr Hussin Rothan, Researcher, Faculty of Medicine, University of Malaya, Kuala Lumpur , Malaysia
Antibodies as a limitless source of peptides with innate microbicidal and immunomodulatory activity (ultrabodies) Professor Luciano Polonelli, Full University Professor, University of Parma, Italy
Octapeptins revisited Dr Tony Velkov, Monash Institute of Pharmaceutical Sciences, Victoria, Australia
Using molecular simulations to understand the dual action of peptides in antimicrobial activity and innate immune modulation Dr Peter J Bond, Principal Investigator Bioinformatics Institute, A*STAR, Singapore. Adjunct Assist. Professor, Dept. Biological Sciences, National University of Singapore, Singapore
Preclinical development of a novel synthetic antimicrobial peptide for lung infections and sepsis Dr Alessandro Pini, Dept. of Medical Biotechnology, University of Siena, SetLance srl Toscana Life Sciences, Italy
Enhancing Host Resistance against Lethal Infections Professor Roger M. Loria, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
Echinoderms as source of novel antimicrobial peptides to contrast human pathogens Dr Domenico Schillaci, Lecturer, University of Palermo, Palermo, Italy
War against Microbes: are Antibiotics the only Weapons? Dr. Jayanta Haldar, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India
Antibiotics in Modulation of M1 and M2 Macrophage Responses Dr Charles Mills, BioMedical Consultants, USA
Probiotic bacteria against multiresistant pathogens Professor Iryna Sorokulova, Auburn University, Auburn, AL, USA
Antibiotic therapy corroborated by selected immunomodulating beta blockers Dr. Karin Peuschel, CNP, Switzerland
Clinical Application of Probiotics in Antibiotic Therapy: the Current and Future Use Dr Thomas A. Tompkins, Research Director, Lallemand Health Solutions Inc, Montreal, Canada
|
|
|
|
|
|
Deadline for Abstracts:
|
|
August 10th 2014
|
|
|
|
|
|
Registration:
|
|
Click here to register
|
|
E-mail:
|
|
enquiries@euroscicon.com
|
|
|
|
|
|
|
|